Tests canagliflozin for inflammation in blood vessels of people with diabetes and heart disease
Compares canagliflozin with a placebo in adults with type 2 diabetes and coronary artery disease.
Plain-language title generated from the registry record
Registry title: Canagliflozin Targeting Vascular Inflammation
Key facts
- Where
- Ottawa, CanadaSee the site
- Phase
- Phase 2/3
Where in Canada
- University of Ottawa Heart InstituteOttawa, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ottawa Heart Institute Research Corporation
- Trial code
- NCT05427084
- Record updated
- 6 May 2026
- Original description
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.Read full original descriptionShow less
Canagliflozin Targeting Vascular Inflammation: An Ottawa Imaging Study - A Pilot Study
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.
Inclusion: 1) Stable CAD (over 60 days post-myocardial infarction); 2) Diabetes; 3) given informed consent.
Exclusion: Use of p-glycoprotein inhibitor (e.g. cyclosporine, verapamil, or quinidine) or a strong CYP3A4 inhibitor (e.g. ritonavir, clarithromycin, or ketoconazole); decompensated heart failure; active infection (e.g. pneumonia, active skin infections, and on antibiotics); active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate)); glomerular filtration rate (GFR) <50 ml/min/1.72m2; Hemoglobin < 105(women) <110 (men) g/L; WBC < 3.0x 10(9)/L, platelet count< 110x 10(9)/L; Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease or with alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal; severe LV dysfunction (EF<50%); pregnancy (all women of child bearing potential will have a negative BHCG test; breastfeeding; Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception; unable to give informed consent.